Authors
Latest:
Improving Access to Stroke Systems of Care: Mitchell S.V. Elkind, MD, MS, MPhilThe president of the American Heart Association discussed the necessary steps to increase access to systems of care in order to improve health overall, including the integration of telemedicine.
Latest:
Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MDA trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Latest:
Cure CMD: Benefits of the Biennial SciFam ConferenceRachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.
Latest:
Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhDThe postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]
Latest:
The Art of Patient Assessment and Knowledge of Treatment Options in Migraine: Dolores D. Santamaria, MDThe director of the Headache Center at Allegheny Health Network talked about the evolution of migraine treatments and highlighted the importance of personalized medicine for patients living with this disabling condition. [WATCH TIME: 10 minutes]
Latest:
Sleeping Around the Podcast: Living with Narcolepsy & Cataplexy: The Patient's PerspectiveSleeping Around the Podcast is joined by Rachel Nesmith, a patient with narcolepsy, who shares her story of overcoming the burdens and impairments of living with narcolepsy and cataplexy.
Latest:
Identifying and Treating Progression in MS Beyond Relapses: Celia Oreja-Guevara, MD, PhDThe vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]
Latest:
VIDEO: Narcolepsy: From Diagnosis to Treatment—Insights From the Front LinesPanelists discuss the clinical presentation, diagnostic approaches, and treatment considerations for narcolepsy, offering practical insights to guide health care professionals new to its diagnosis and management.
Latest:
AUPN 2022 Veterans Health Administration WorkshopGlenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Latest:
Using Integrative Neurology and Personalized Medicine to Transform Care in 2025: Sushma Kola, MDThe director of Integrative Neurosciences at Allegheny Health Network talked about integrative neurology, personalized medicine, and emerging diagnostic tools that enhance patient-centered care. [WATCH TIME: 5 minutes]
Latest:
NeurologyLive® Clinician of the Month Spotlight: Stephanie C. Randle, MD, MSAs part of our monthly clinician spotlight, NeurologyLive® highlighted epilepsy expert Stephanie C. Randle, MD, MS, director of the Tuberous Sclerosis Complex Clinic at Seattle Children's Hospital.
Latest:
Finding Positivity Through Adversity in Poststroke Care: Harmony Sierens, MDThe medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital discussed the importance of early intervention, sustained care, and rehabilitation in managing poststroke patients. [WATCH TIME: 4 minutes]
Latest:
Patient and Clinical Perspectives on Advancing MS Care Through Treatment, Advocacy, and ResearchA patient and neurologist discussed personal and professional perspectives on treatment initiation, ongoing research, and patient advocacy in multiple sclerosis. [WATCH TIME: 5 minutes]
Latest:
Emerging Agents in Alzheimer’s DiseasePanelists discuss how emerging therapeutic targets, including amyloid-beta plaques, tau protein aggregation, inflammation modulation, and mitochondrial dysfunction, offer promising approaches for disease-modifying treatments in early Alzheimer's disease.
Latest:
Key Takeaways and Future Opportunities for WVE-004: Michael Panzara, MD, MPHThe chief medical officer of Wave Life Sciences outlined the FOCUS-C9 study, which has incorporated feedback from patients with both ALS and FTD, as well as investigators in the research field.
Latest:
Stephen Cunnane, PhD: Evaluating Ketogenics in Brain Energy RescueThe professor from the Universite de Sherbrooke discusses the use of ketogenic diets and supplements to increase cognition.
Latest:
Rethinking Neurology Education With AI: A Preview of ANA/AUPN 2025Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.
Latest:
Future Research Directions for DCTclock and the Potential to Predict Alzheimer Biomarkers: Ali Jannati, MD, PhDThe manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]
Latest:
Building a Large-Scale Database of Genetic Associations to Alzheimer Disease: Margaret Pericak-Vance, PhDThe director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]
Latest:
Expanding Research of Sleep and Cognitive Risks Associated: Christian Agudelo, MDThe Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine discussed observing how sleep may impact cognitive decline in different populations.
Latest:
Evaluating 3K3A-APC in Patients With ALS: Kent Pryor, PhDThe CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
Latest:
Incorporation of Registered Dietitians in MS Care: Tyler Titcomb, PhD, RDN, IFMCPThe postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]
Latest:
Let’s Get Moving: A Multidisciplinary Approach to Gait Rehabilitation in Multiple SclerosisCurrent research pushes to advance therapeutic possibilities and understand underlying neural mechanisms for gait impairments in individuals with the disease.
Latest:
Muscular Dystrophy Association: A Hybrid Conference Featuring the Latest Advances in Neuromuscular Research, Therapy, and Clinical CareThe Muscular Dystrophy Association's annual meeting will take place in-person and virtually in Nashville, Tennessee, on March 13-16, with more than 950 in-person attendees and 130 presenters.
Latest:
Future of Cognition in Multiple SclerosisAhmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.
Latest:
Clinicians Express Growing Optimism in ALS Research and Treatment AdvancementsExperts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]
Latest:
Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DOThe professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]
Latest:
Therapeutics Aim at Modifying Alzheimer DiseaseDisease-modifying agents will require early detection, including comprehensive evaluation of disease severity and alternative or confounding diagnoses. When the long-awaited moment arrives, when disease-modifying therapies finally are available for ADRDs…will we be ready?
